Research and Treatment

Research & Treatment

Updates on Daklinza, Technivie, and the ACE910 trial
NHF is committed to the training and support of clinician-researchers in hematology.
NHF awarded 5 JGP Fellowships in 2014.
There are times when less really is more. With the June 6, 2014, US Food and Drug Administration (FDA) approval...
Progress. For years, the bleeding disorders community has been waiting for meaningful progress for a greater understanding of hemophilia, for...
A six-year study by the US Centers for Disease Control and Prevention (CDC) of patients with inhibitors, antibodies to infused...
This interview was conducted with Rachael Grace, MD, MMSc, Director, Hematology Clinic, Boston Children’s Hospital. The fellowship was funded from...
HemAware is conducting a series of interviews with recipients of the NHF-Shire Clinical Fellowship. It is funded through the generous...
This interview was conducted with Salley Pels, MD, assistant professor of pediatrics and associate medical director at the Yale Hemostasis...
When the US Food and Drug Administration (FDA) approved Tivicay ® (dolutegravir), a new drug to treat HIV, in August...
Update, November 2014: The St. Jude/UCL gene therapy trial now has data from all 10 participants, to be published in...
HemAware is conducting a series of interviews with recipients of the NHF-Shire Clinical Fellowship. It is funded through the generous...
Chat Icon
Need Info? Ask NHF!
Contact HANDI, NHF's resource center for additional information on bleeding disorders.